There are 2934 resources available
4707 - NIVOREN GETUG-AFU 26 translational study:CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).
Presenter: Yann Vano
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4823 - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
Presenter: Toni Choueiri
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
3170 - A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC
Presenter: Eric Jonasch
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
3527 - Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus AXitinib (AX) Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC)
Presenter: Toni Choueiri
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
3113 - APACHE: an open label, randomized, phase 2 study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with refractory germ cell tumors (GCT): results from the expanded combination therapy cohort
Presenter: Elena Farè
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4447 - Prognostic factors in metastatic seminomatous germ cell tumors and elevated human chorionic gonadotrophin (HCG) – a study of the G3
Presenter: Christoph Seidel
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4145 - Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 countries
Presenter: Rachel Giles
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
1057 - TRIUMPH: Primary Efficacy of a Phase II Trial of Trastuzumab (T) and Pertuzumab (P) in Patients (pts) with Metastatic Colorectal Cancer (mCRC) with HER2 (ERBB2) Amplification (amp) in Tumor Tissue or Circulating Tumor DNA (ctDNA): A GOZILA Sub-study
Presenter: Yoshiaki Nakamura
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
4795 - Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
Presenter: John Strickler
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
2951 - Impact of clonality and DNA repair mutations on plasma tumor mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26
Presenter: Jonathan Loree
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract